Too much of a good thing: Important mechanism in hormone-sensitive breast cancer uncovered
Two thirds of breast cancers are ERalpha-positive, i.e., many estrogen receptors of the ERalpha- type are found in their cells. “These molecules can interact with the estrogen hormone and, thus, even lead to cancer,” explains Dr. Joerg Hoheisel; mol…
Infant estrogen levels tracked through diaper research
With the help of babies and more than 5,000 of their diapers, Emory University researchers have developed an accurate, noninvasive method to determine estrogen levels in infants.
The method, previously used in nonhuman primates, will allow re…
PET scans reveal estrogen-producing hotspots in human brain
UPTON, NY – A study at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory has demonstrated that a molecule “tagged” with a radioactive form of carbon can be used to image aromatase, an enzyme responsible for the production of estro…
Estrogen replacement therapy speeds ovarian cancer growth, new study reports
Aurora, Colo. (Oct. 19, 2010) — Estrogen therapy used by menopausal women causes a type of ovarian cancer to grow five times faster, according to a new study by researchers at the University of Colorado Cancer Center.
Menopausal estrogen replace…
Scripps Research study challenges conventional theory of modern drug design
JUPITER, Fl, October 7, 2010 — Scientists from The Scripps Research Institute have uncovered new evidence that challenges the current theory about a process key to the way modern drugs are designed and how they work in the human body.
The new st…
Combined hormone replacement therapy boosts stroke, dementia
Last March, a multi-center national study made headlines by concluding that taking a combination of the hormones estrogen and progestin did not improve the quality of life for women who are free of menopause-related symptoms but did expose them to a slightly higher risk of heart attacks, strokes and breast cancer. For that reason, many medical scientists began recommending against the combined therapy in the absence of such symptoms, saying the risks of estrogen plus progestin outweighed the benefits.
Estrogen plus progestin not helpful to quality of life in postmenopausal women
Taking a combination of the hormones estrogen and progestin does not improve the quality of life for women who are free of menopause-related symptoms, but does expose them to a slightly higher risk of heart attacks, strokes and breast cancer, a new multi-center national study concludes. For that reason, medical scientists now recommend against the combined therapy in the absence of such symptoms.
Link found between estrogen, changes in brain structure, and learning and memory
Scientists have discovered how estrogen initiates physical changes in rodent brain cells that lead to increased learning and memory — a finding, the researchers contend, that illustrates the likely value of the hormone to enhance brain functioning in women. Their study, published in the March 15 issue of The Journal of Neuroscience, describes for the first time a chain of molecular events that is activated in the brain’s primary memory center, called the hippocampus, when estrogen bathes nerve cells.
Animal studies confirm hormone replacement can improve learning
For estrogen to enhance learning and memory, nerve cells in the brain called cholinergic neurons are essential to the process, suggest animal studies performed by researchers from the University of Pittsburgh School of Pharmacy. “Estrogen replacement in postmenopausal women has important effects on mood and cognition. This research was focused on trying to understand what estrogen does in the brain to reduce the effects on brain aging and cognitive decline,” said Robert Gibbs, associate professor of pharmaceutical sciences at the University of Pittsburgh School of Pharmacy.
Progesterone Causes Less Bleeding than Most Hormone Replacement Therapies
Excessive bleeding, a troublesome side-effect that causes many women to stop taking hormone replacement therapies (HRT), is less likely with progesterone than with more commonly used synthetic versions. Results from a national clinical trial published in the November issue of the Journal of Obstetrics and Gynecology, show that a combination of estrogen and micronized progesterone (MP) causes fewer days and less intense bleeding than the most commonly used combination. Previous studies have shown that unacceptable bleeding is the reason that most women discontinue HRT during the first year of therapy.